Trials / Completed
CompletedNCT01253707
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
First in human, open-label, sequential dose escalation and expansion study of AMG 337 in subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 337 | AMG 337 is a small molecule inhibitor of c-Met which is a receptor tyrosine kinase expressed on the surface of epithelial cells. |
Timeline
- Start date
- 2010-12-08
- Primary completion
- 2015-10-01
- Completion
- 2016-12-13
- First posted
- 2010-12-03
- Last updated
- 2022-11-07
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01253707. Inclusion in this directory is not an endorsement.